市場調査レポート

ラテラルフロー技術および将来のポイントオブケア診断

Lateral Flow Technology And The Future Of Point Of Care Diagnostics, 2nd Edition

発行 Kalorama Information 商品コード 48557
出版日 ページ情報 英文 210 Pages
即納可能
価格
本日の銀行送金レート: 1USD=102.85円で換算しております。
Back to Top
ラテラルフロー技術および将来のポイントオブケア診断 Lateral Flow Technology And The Future Of Point Of Care Diagnostics, 2nd Edition
出版日: 2013年08月01日 ページ情報: 英文 210 Pages
概要

ラテラルフロー試験は、免疫クロマトグラフィーストリップ(ICS)試験としても知られ、試験結果を待つのに費やす時間を数時間から数分へと短縮し、オペレーターのトレーニングが少なくて済み、またデバイス開発・治療のどちらのコストをも削減するポイントオブケア(POC)試験です。

当レポートでは、ラテラルフローPOC試験の市場、技術、および動向について、患者によるセルフテストおよび医療専門家によるPOC検査の双方について詳細に調査分析し、ラテラルフロー(LF)製品の現在の売上と予測、LF試験収益の増加を促進する主な要因、LF-POC市場のセルフテスト・専門家による試験の分析、主要セグメント別の市場分析、および主要企業のプロファイルなどを提供しており、概略下記の構成でお届けいたします。

第1章 エグゼクティブサマリー

第2章 イントロダクション

第3章 ラテラルフロー装置の技術的課題・革新

  • ラテラルフロー装置の技術的課題・障壁
  • 代替試験サンプル
  • ラテラルフロー試験結果の自動読み取り
  • 接続性
  • 分子診断におけるラテラルフロー(核酸側方流動)
  • ラテラルフローと競合する新興技術

第4章 課題・動向

  • 特許に着目した促進因子
  • 医療/ヘルスケア関連の促進因子
  • 技術促進因子
  • 経済的促進因子
  • その他の促進因子
  • ラテラルフローPOC試験のメリット・デメリット

第5章 市場分析

  • 市場概要
  • 市場の現況と予測
  • ラテラルフローPOC試験
  • 世界市場におけるラテラルフローPOC試験・迅速検査
    • 米国
    • 欧州
    • その他
  • 市場セグメント:試験分類別
    • 生殖(妊娠・排卵・閉経)
    • 感染症
    • HIV POC試験
    • インフルエンザ
    • 結核
    • 心臓マーカー
    • 腫瘍マーカー
    • 毒物乱用・アルコール
    • その他
  • ラテラルフローPOC試験のロケーション

第6章 主なラテラルフローPOC試験・迅速検査装置の販売企業

第7章 主なラテラルフローPOC試験・迅速検査装置市場参入企業

  • Alverix, Inc.
  • Arbor Vita Corporation
  • Axxin
  • BioAMD Ltd.
  • BioMedomics
  • Corgenix Medical Corporation
  • Epinex Diagnostics, Inc.
  • Genisphere, LLC
  • GenPrime, Inc.
  • Mesa Tech International, Inc.
  • TwistDx, Ltd.
  • Venaxis, Inc. (Formerly Aspen BioPharma, Inc.)

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: KLI5093826

Lateral flow tests, also known as immunochromatographic strip (ICS) tests, are point of care tests that reduce the time spent waiting for test results from hours to minutes, require less training for operators, and reduce the cost of both device development and care. This report, Lateral Flow Technology and the Future of Point of Care Testing, 2nd Edition, takes an in depth look at the market, technologies, and trends in lateral flow point-of-care testing, looking at both self-testing by patients and at point-of-care testing by healthcare professionals.

Lateral flow (LF) devices and tests have been a popular platform for rapid immunoassays since their introduction in the mid-1980s, and since our last look at the market there has been continued interest and innovations. This report profiles over a hundred companies that currently market lateral flow tests. Many of these companies, plus more than ten additional companies, are developing innovations in lateral flow-based devices. Companies profiled in this report lateral flow technology to develop and market a wide range of rapid tests for market segments of in vitro diagnostic (IVD) tests that can be performed in centralized laboratories.

Every critical aspect of the lateral flow test market is addressed, including the following key topics:

  • The current sales figures for LF productsand realistic projections for 2017
  • The core factors driving LF testing revenues up.
  • Breakout of LF-POC market by Self Test and Professional

Breakout of LF-POC market by Key Test Segments (Fertility, Infectious Disease, Cardiac Markers, Oncology, Drugs of Abuse, Other)

  • Need-to-know companies in Lateral Flow Test devices.
  • The trends to watch that could increase sales predictions.
  • Expected gains to be made by LF POC devices over lab-based immunoassays across categories.
  • Regional markets for lateral flow tests (US, Europe, Japan, ROW)
  • Companies launching innovative devices.
  • Obstacles that could trap new entrants.

Growth in lateral flow point-of-care testing is being fueled by many factors fueling growth of the point-of-care market as a whole. These include the globalization of infectious diseases and the associated public health issues, advances in therapies giving physicians more tools for treatment of patients if the doctor is able to rapidly diagnose the problem, the need to monitor an ever-growing group of people with chronic diseases such as cardiovascular diseases, cancer and other chronic conditions, and many other factors. Decentralized testing and the ability to get rapid test results is emerging as a tool for more efficient diagnosis and patient evaluation, and to improve the quality of patient care.

This report provides a realistic assessment acknowledging the reality of payors' emphasis on cost/benefit analysis for new technologies. Current sales and predictions for 2017 sales are provided for the diabetes, oncology, cardiac marker, pregnancy and other LF test markets.

Kalorama's unique and thorough research process provides an exhaustive analysis of this evolving market. Information was gathered using both primary and secondary research including comprehensive research of secondary sources such as company literature, databases, investment reports, and medical and business journals.

For the purpose of this study, Kalorama Information conducted telephone and email interviews with key industry officials, consultants, health care providers, and government personnel. These sources were the primary basis in gathering information specifically relating to revenue and market share data presented in this report. Specific interviews with device company representatives included marketing directors, division managers, and product development representatives.

The report offers a quantitative assessment of specific markets, worldwide, in U.S. dollars for 2012 to 2017.

Table of Contents

CHAPTER ONE: EXECUTIVE SUMMARY

  • Overview
  • Scope and Methodology
  • Market Overview

CHAPTER TWO: INTRODUCTION

  • Background - PointofCare and Rapid Testing
  • Overview of Lateral Flow Devices
  • Point of View

CHAPTER THREE: TECHNICAL ISSUES AND INNOVATIONS FOR LATERAL FLOW DEVICES

  • Technical Issues and Hurdles with Lateral Flow Devices
  • Alternate Test Samples
  • Automating Reading of Lateral Flow Test Results
  • Connectivity
  • Innovations with Lateral Flow Devices
  • Lateral Flow in Molecular Diagnostics [Nucleic Acid Lateral Flow]
  • Emerging Technologies Competing Against Lateral Flow

CHAPTER FOUR: ISSUES AND TRENDS

  • Patent focused drivers
  • Medical/Healthcare related drivers
  • Technology drivers
  • Economic drivers
  • Other drivers
  • Advantages and Disadvantages of Lateral Flow POC Testing
  • Advantages:
  • Disadvantages:

CHAPTER FIVE: MARKET ANALYSIS

  • Market Overview
  • Current Markets and Market Forecasts -
  • Lateral Flow PointofCare Testing
  • Self Testing/OTC
  • Professional Lateral Flow PointofCare Testing
  • Lateral Flow POC Testing and Rapid Testing in World Markets
  • The United States
  • Europe
  • Rest of World
  • Market Segments by Test Category
  • Fertility (Pregnancy, Ovulation, and Menopause)
  • Infectious Disease
  • HIV POC Testing
  • Influenza
  • Tuberculosis
  • Cardiac Markers
  • Oncology Markers
  • Drugs of Abuse and Alcohol
  • Other Lateral Flow PointofCare Tests
  • Locations for Lateral Flow PointofCare Testing

CHAPTER SIX: COMPANIES MARKETING LF POC/RAPID TEST DEVICES

  • 1 Step Detect Associates, LLC
  • Access Bio, Inc.
  • AccuBioTech Co., Ltd.
  • Accumed Biology (Shanghai) Co., Ltd.
  • Accutech, LLC
  • Alere Inc.
  • Recent Revenue History:
  • Amedica Biotech
  • American Bio Medica Corporation
  • Recent Revenue History:
  • Company Overview and POC Products:
  • Apacor Ltd.
  • Artron Laboratories Inc.
  • Atlas Link Biotech Co., Ltd.
  • Augurix SA/Augurix Diagnostics
  • Autobio Diagnostics Co., Ltd.
  • AZOG, Inc.
  • BD (Becton Dickinson)
  • Recent Revenue History:
  • Company Overview and POC Products:
  • Beckman Coulter, Inc. (Subsidiary of Danaher Corporation)
  • Recent Revenue History:
  • Company Overview and POC Products:
  • Biocare Diagnostics Ltd.
  • Biomerica, Inc.
  • Recent Revenue History
  • Company Overview and POC Products
  • bioMérieux sa
  • Recent Revenue History
  • Company Overview and POC Products:
  • Recent Revenue History
  • Company Overview and POC Products
  • BioScan Screening Systems, Inc
  • BioSino BioTechnology and Science Inc.
  • Blue Cross Biomedical Co., Ltd.
  • BNTX Inc
  • Boson Biotech Co., Ltd.
  • Branan Medical Corporation
  • BÜHLMANN Laboratories AG
  • Calypte Biomedical Corporation
  • Recent Revenue History
  • Company Overview and POC Products
  • Recent Revenue History
  • Company Overview and POC Products
  • Dr. Fooke Laboratorien GmbH
  • DRG International, Inc.
  • Recent Revenue History
  • Embryotech Laboratories
  • Enterix Inc. (A Quest Diagnostics Company)
  • Eurospital Spa
  • Express Diagnostics International
  • EY Laboratories, Inc.
  • First Check Diagnostics Corp. (Subsidiary of Alere)
  • First Diagnostic LLC
  • GenBio
  • Germaine Laboratories
  • Healgen Scientific LLC
  • Hema Diagnostic Systems, LLC (HDS)
  • Hemosure, Inc.
  • Hightop Biotech Co., Ltd.
  • IDenta Corporation
  • ImmunoMycologics, Inc.
  • ImmunoScience, Inc.
  • Immunostics, Inc
  • InBios International, Inc.
  • Instant Technologies, Inc.
  • InTec Products, Inc.
  • International ImmunoDiagnostics
  • Jant Pharmacal Corporation
  • Jei Daniel Biotech Corp.
  • Labsystems Diagnostics Group (Formerly Ani Biotech Oy)
  • Labtest
  • LifeSign LLC
  • Liming BioProducts Co., Ltd.
  • MagnaBioSciences, LLC
  • MAVAND Solutions GmbH
  • Medisensor, Inc.
  • Mediwatch Plc
  • Medix Biochemica
  • MedMira Inc.
  • Recent Revenue History
  • Company Overview and POC Products
  • Recent Revenue History
  • Company Overview and POC Products
  • Recent Revenue History
  • Company Overview and POC Products
  • Polymed Therapeutics, Inc.
  • Precheck Bio, Inc.
  • Prestige Diagnostics
  • Preventis GmbH
  • Princeton Biomeditech Corporation
  • Quidel Corporation
  • Recent Revenue History
  • Company Overview and POC Products
  • RBiopharm AG
  • Real World Diagnostics
  • Redwood Toxicology Laboratory, Inc.
  • ReLIA Diagnostics, Inc.
  • RENESA UG
  • Recent Revenue History
  • Company Overview and POC Products
  • Reszon Diagnostics International Sdn. Bhd.
  • SA Scientific
  • Savyon Diagnostics
  • Screening Devices Canada, Inc.
  • Sekisui Medical Co., Ltd.
  • Serascience
  • Sichuan Maker Biotechnology Co., Ltd.
  • Standard Diagnostics (Part of Alere)
  • SureScreen Diagnostics
  • Syntron Bioresearch, Inc.
  • Systagenix Wound Management
  • TECHLAB, Inc.
  • Teco Diagnostics
  • Theradiag
  • Trinity Biotech plc
  • Recent Revenue History
  • Company Overview and POC Products
  • Turklab Medical Devices Inc.
  • UCP Biosciences, Inc.
  • US Diagnostics, Inc.
  • VEDA.LAB SA
  • Viricell S.L.
  • WAMA Diagnostica
  • Zhuhai Encode Medical Engineering Co., Ltd.

CHAPTER SEVEN: COMPANIES ENTERING LF POC/RAPID TEST MARKET OR LAUNCHING NOVEL TESTS

  • Alverix, Inc.
  • Arbor Vita Corporation
  • Axxin
  • BioAMD Ltd.
  • BioMedomics
  • Corgenix Medical Corporation
  • Epinex Diagnostics, Inc.
  • Genisphere, LLC
  • GenPrime, Inc.
  • Mesa Tech International, Inc.
  • TwistDx, Ltd.
  • Venaxis, Inc. (Formerly Aspen BioPharma, Inc.)

LIST OF EXHIBITS

CHAPTER ONE: EXECUTIVE SUMMARY

  • Table 11: Lateral Flow Rapid Test Sales, Worldwide, 2012 and 2017

CHAPTER THREE: TECHNICAL ISSUES AND INNOVATIONS FOR LATERAL FLOW DEVICES

  • Table 31: Selected Companies with Saliva or OralFluid Collection Devices
  • Table 32: Selected Companies With Readers for Lateral Flow Devices
  • Table 33: Selected Companies Developing and/or Marketing Innovations in LFT
  • Table 34: Selected Companies Using Lateral Flow in Molecular Diagnostics
  • Table 35: Selected Companies Developing and/or Marketing POC Diagnostic Platforms that May Compete with Lateral Flow Immunoassays

CHAPTER FOUR: ISSUES AND TRENDS

  • Table 41: Selected Companies Outside of North America, Europe, or Japan Marketing Lateral Flow Diagnostic Tests

CHAPTER FIVE: MARKET ANALYSIS

  • Table 51: Lateral Flow OTC/SelfTest Sales by Test Category, Worldwide, 2012 and 2017 (Fertility, Infectious Disease, Cardiac Markers, Oncology, Drugs of Abuse, Other)
  • Table 52: Lateral Flow Professional POC/Rapid Test Sales by Test Category, Worldwide, 2012 and 2017 (Fertility, Infectious Disease, Cardiac Markers, Oncology, Drugs of Abuse, Other)
  • Table 53: PointofCare Test Sales by Region, 2012 and 2017 (All POC Tests)
  • Table 54: Worldwide POC/Rapid Test Sales by Test Category, 2012 and 2017 (Fertility, Infectious Disease, Cardiac Markers, Oncology, Drugs of Abuse, Other)
  • Table 55: Selected Companies Marketing Fertility LFBased Tests
  • Table 56: Selected Companies Marketing Infectious Disease LFBased Tests
  • Table 57: Selected Companies Marketing LFBased Cardiac Marker Tests
  • Table 58: Selected Companies Marketing LF Oncology LFBased Tests
  • Table 59: Selected Companies Marketing Drugs of Abuse LFBased Tests
  • Table 510: Selected Companies Marketing Other LFBased Tests
Back to Top